Perfil epidemiológico dos casos suspeitos de sarampo e rubéola notificados no SINAN, Brasil, 2007 a 2016 / Epidemiological profile of suspected cases of measles and rubella notified on SINAN, Brazil, 2007 to 2016

Descrever os casos suspeitos de sarampo e rubéola notificados no Sistema de Informação de Agravos de Notificação (Sinan), Brasil, 2007 a 2016. Métodos: Os dados foram extraídos do Sinan, referentes aos anos de 2007 a 2016. As variáveis utilizadas foram os números de notificações de casos de sarampo e rubéola por regiões e ano, idade, sexo, hospitalização, estado gestacional, histórico vacinal, realização de bloqueio vacinal, coletas sorológicas (S1 e S2), sinais e sintomas, investigação adequada, critério de confirmação ou descarte e classificação final do caso. Resultados: Entre 2007 e 2016 houve 127.802 casos suspeitos de sarampo e rubéola notificados. Aproximadamente 92% dos casos foram investigados, a maioria em menores de cinco anos. Os sintomas mais frequentes foram tosse (40%) e coriza (38%). Como instrumento de vigilância foi coletado sangue para confirmação laboratorial em 87% das notificações. A maioria dos casos de sarampo ocorreu entre os anos de 2011 e 2015, relacionados a casos importados, totalizando 1.443 casos; para rubéola, 10.125 casos foram confirmados. Foram descartados 1,3% (1.698/127.802) e 5,1% (6.555/127.802) das notificações de sarampo e rubéola, respectivamente. Foram ignorados 9% (11.523/127.802) para sarampo e 49% (62.978/127.802) para rubéola. Conclusão: A vigilância dos casos de doenças exantemáticas permitiu demonstrar a situação dos casos de doenças exantemáticas circulantes no país como importante ferramenta de saúde pública. O grande número de casos descartados classificados como ignorados merece atenção, no sentido de melhorar o encerramento dos casos suspeitos notificados

To describe the suspected cases of measles and rubella notified in the Notifiable Diseases Information System (Sinan), Brazil, from 2007 to 2016. Methods: Data were extracted from Sinan referring to the years 2007 to 2016. The variables used were the number of notifications of measles and rubella cases by region and year, age, gender, hospitalization, gestational status, vaccination history, vaccination blockade, serological collections (S1 and S2), signs and symptoms, adequate investigation, confirmation criteria or disposal and final case classification. Results: Between 2007 and 2016, there were 127,802 suspected cases of measles and rubella reported. Approximately 92% of cases were investigated, mostly in children under five years of age. The most frequent symptoms were cough (40%) and runny nose (38%). As a surveillance tool, blood was collected for laboratory confirmation in 87% of notifications. Most Measles cases occurred between 2011 and 2015, related to imported cases, totaling 1,443 cases; for Rubella 10,125 cases were confirmed. 1.3% (1,698/127,802) and 5.1% (6,555/127,802) of measles and rubella notifications, respectively, were discarded. 9% (11,523/127,802) for measles and 49% (62,978/127,802) for rubella were ignored. Conclusion: Surveillance of cases of exanthematous diseases allowed demonstrating the situation of cases of exanthematous diseases circulating in the country as an important public health tool. The large number of discarded cases classified as ignored deserves attention, in order to improve the closing of notified suspected cases

Analysis of the direct economic burden of measles cases and its influencing factors in Shanghai from 2017 to 2019 / 中华预防医学杂志

Objective: To analyze the direct economic burden caused by measles cases in Shanghai from 2017 to 2019 and its influencing factors. Methods: A total of 161 laboratory-confirmed measles cases reported from January 1, 2017, to December 31, 2019, in Shanghai were included in the study through the "Measles Surveillance Information Reporting and Management System" of the "China Disease Surveillance Information Reporting and Management System". Through telephone follow-up and consulting hospital data, the basic information of population, medical treatment situation, medical treatment costs and other information were collected, and the direct economic burden of cases was calculated, including registration fees, examination fees, hospitalization fees, medical fees and other disease treatment expenses, as well as transportation and other expenses of cases. The multiple linear regression model was used to analyze the main influencing factors of the direct economic burden. Results: The age of 161 measles cases M (Q1, Q3) was 28.21 (13.33, 37.00) years. Male cases (56.52%) were more than female cases (43.48%). The largest number of cases was≥18 years old (70.81%). The total direct economic burden of 161 measles cases was 540 851.14 yuan, and the per capita direct economic burden was 3 359.32 yuan. The direct economic burden M (Q1, Q3) was 873.00 (245.01, 4 014.79) yuan per person. The results of multiple linear regression model analysis showed that compared with other and unknown occupations, central areas and non-hospitalized cases, the direct economic burden of measles cases was higher in scattered children, childcare children, students, and cadre staff in the occupational distribution, suburban areas and hospitalized, with the coefficient of β (95%CI) values of 0.388 (0.150-0.627), 0.297 (0.025-0.569), 0.327 (0.148-0.506) and 1.031 (0.853-1.209), respectively (all P values<0.05). Conclusion: The direct economic burden of some measles cases in Shanghai is relatively high. Occupation, area of residence and hospitalization are the main factors influencing the direct economic burden of measles cases.

Vigilancia de enfermedades febriles exantemáticas / Surveillance of febrile diseases

Actualización mundial sobre sarampión a marzo de 2022, y datos en la región de las Américas y en Argentina. Se presentan los datos de casos notificados en la Ciudad de Buenos Aires, a la Semana Epidemiológica 12 de 2022, cobertura de vacunación, y acciones de vigilancia epidemiológica.

Measles resurgence in Brazil: analysis of the 2019 epidemic in the state of São Paulo / Ressurgimento do sarampo no Brasil: análise da epidemia de 2019 no estado de São Paulo

ABSTRACT OBJECTIVE To analyze the epidemiological profile of cases and the pattern of spatial diffusion of the largest measles epidemic in Brazil that occurred in the post-elimination period in the state of São Paulo. METHOD A cross-sectional study based on confirmed measles cases in 2019. Bivariate analysis was performed for socioeconomic, clinical, and epidemiological variables, according to prior vaccination and hospitalization, combined with an analysis of spatial diffusion of cases using the Inverse Distance Weighting (IDW) method. RESULTS Of the 15,598 confirmed cases, 2,039 were hospitalized and 17 progressed to death. The epidemic peak occurred in epidemiological week 33, after confirmation of the first case, in the epidemiological week 6. Most cases were male (52.1%), aged between 18 and 29 years (38.7%), identified as whites (70%). Young adults (39.7%) and children under five years (32.8%) were the most affected age groups. A higher proportion of previous vaccination was observed in whites as compared to Blacks, browns, yellows and indigenous people (p < 0.001), as well as in the most educated group compared to the other categories (p < 0.001). The risk of hospitalization was higher in children than in the older age group (RI = 2.19; 95%CI: 1.66-2.88), as well as in the unvaccinated than in the vaccinated (RI = 1.59; 95%CI: 1.45-1.75). The pattern of diffusion by contiguity combined with diffusion by relocation followed the urban hierarchy of the main cities' regions of influence. CONCLUSION In addition to routine vaccination in children, the findings indicate the need for immunization campaigns for young adults. In addition, studies that seek to investigate the occurrence of clusters of vulnerable populations, prone to lower vaccination coverage, are essential to broaden the understanding of the dynamics of transmission and, thus, reorienting control strategies that ensure disease elimination.

RESUMO OBJETIVO Analisar o perfil epidemiológico dos casos e o padrão de difusão espacial da maior epidemia de sarampo do Brasil ocorrida no período pós-eliminação, no estado de São Paulo. MÉTODO Estudo transversal, baseado em casos confirmados de sarampo em 2019. Foi conduzida análise bivariada das variáveis socioeconômicas, clínicas e epidemiológicas, segundo vacinação prévia e ocorrência de hospitalização, combinada a uma análise de difusão espacial dos casos por meio da metodologia de interpolação pela ponderação do inverso da distância. RESULTADOS Dos 15.598 casos confirmados, 2.039 foram hospitalizados e 17 evoluíram para o óbito. O pico epidêmico ocorreu na semana epidemiológica 33, após a confirmação do primeiro caso, na semana epidemiológica 6. A maioria dos casos era homem (52,1%), com idade entre 18 e 29 anos (38,7%), identificados como brancos (70%). Adultos jovens (39,7%) e menores de cinco anos (32,8%) foram as faixas etárias mais acometidas. Observou-se maior proporção de vacinação prévia em brancos, quando comparados a pretos, pardos, amarelos e indígenas (p < 0,001), assim como no grupo mais escolarizado, quando comparado às demais categorias (p < 0,001). O risco de hospitalização foi maior em crianças, quando comparado à faixa etária mais idosa (RI = 2,19; IC95% 1,66-2,88), assim como entre não vacinados, quando comparado a vacinados (RI = 1,59; IC95% 1,45-1,75). O padrão de difusão por contiguidade combinado à difusão por realocação seguiu a hierarquia urbana das regiões de influência das principais cidades. CONCLUSÃO Além da vacinação de rotina em crianças, os achados indicam a necessidade de campanhas de imunização de adultos jovens. Adicionalmente, estudos que busquem investigar a ocorrência de clusters de populações vulneráveis, propensas a menor cobertura de vacinação, são essenciais para ampliar a compreensão sobre a dinâmica de transmissão da doença e, assim, reorientar estratégias de controle que garantam a eliminação da doença.

Measles outbreak during the COVID-19 pandemic in Mexico / Brote de sarampión durante la pandemia de COVID-19 en México

Abstract Measles is an exanthematous disease caused by a virus of the Morbillivirus genus. On February 23, 2020, the exanthema began in the first confirmed case of measles this year. At the same time, on February 28, 2020, the first case of the new coronavirus disease (COVID-19) was confirmed. Up to June 6, 2020, 176 measles cases have been confirmed: 137 in Mexico City, 37 in the state of Mexico, and two in the state of Campeche. In Mexico City, municipalities with more cases were Gustavo A. Madero, Miguel Hidalgo, and Iztapalapa; in the State of Mexico were Ecatepec, Tlalnepantla, and Netzahualcoyotl; in Campeche, there are only two cases reported. On the other hand, 7,065,133 cases of COVID-19 have been registered worldwide with a global case fatality rate of 5.7%. In Mexico, there have been 113,619 confirmed cases and 13,511 deaths, while in Mexico City, there have been 30,223 cases and 3062 deaths. Iztapalapa and Gustavo A. Madero are the locations with more cases reported. Hence, a campaign of social distancing started as part of the strategies to control the spread of the infection. The potential threat is that as social confinement measures are relaxed and mobility is initiated, both viruses could continue to spread. It is expected that due to the time that has passed since the last reported measles case, control of this disease will be achieved.

Resumen El sarampión es una enfermedad exantemática causada por un virus del género Morbilivirus. El 23 de febrero de 2020 inició el exantema en el primer caso confirmado en este año; el 28 de febrero de 2020 se confirmó el primer caso de enfermedad por un nuevo coronavirus (COVID-19). Hasta el 6 de junio de 2020 se han confirmado 176 casos de sarampión: 137 en la Ciudad de México, 37 en el Estado de México y 2 en Campeche. En la Ciudad de México, las alcaldías con más casos son Gustavo A. Madero, Miguel Hidalgo e Iztapalapa; en el Estado de México, la mayoría de los casos se presentan en Ecatepec, Tlalnepantla y Netzahualcóyotl; en el estado de Campeche solo se han reportado dos casos. Hasta el 6 de junio de 2020 se habían registrado en todo el mundo 7,065,33 casos de COVID-19, con una letalidad global del 5.7%. En México se han presentado 113,619 casos confirmados y 13,511 muertes; de ellos, 30,223 casos y 3,062 muertes en la Ciudad de México, siendo las alcaldías de Iztapalapa y Gustavo A. Madero las que han tenido el mayor número de casos. Como parte de las estrategias para controlar la diseminación de la infección, se decidió iniciar la campaña de distanciamiento social. La amenaza latente es que, al disminuir las medidas de confinamiento social e iniciar la movilidad paulatina, podrían continuar diseminándose ambos virus. Se espera que debido al tiempo transcurrido desde el último caso de sarampión reportado se logre el control de esta enfermedad.

SUVISA-GVE/Sarampo - Informe 28 / SUVISA-GVE/Measles - Report 28

O Sarampo é uma doença viral aguda, altamente transmissível, caracterizada por febre, exantema e sintomas respiratórios. É uma doença grave, principalmente em crianças menores de cinco anos, desnutridos e imunodeprimidos. A transmissão do sarampo é direta, pessoa a pessoa, através das secreções nasofaríngeas, expelidas ao tossir, espirrar, falar ou respirar. Em 1992 o Brasil elaborou o Plano Nacional de Eliminação do Sarampo como estratégia para eliminação da doença. No ano de 2000 foram confirmados os últimos surtos autóctones nos estados do Acre (AC) e Mato Grosso do Sul (MS). Devido baixas coberturas vacinais, a partir de 2016 o Brasil passou a enfrentar surtos de sarampo em diversos Estados, com elevado número de casos da doença. Em 2018, a ocorrência do surto instalado predominantemente nos Estado do Amazonas e Roraima, registrando 10.351 casos de sarampo, 12 óbitos e a prevalência em um período superior a 12 meses, levou o Brasil a perder a certificação de eliminação do sarampo em fevereiro de 2019

Measles is an acute, highly transmissible viral disease characterized by fever, rash and respiratory symptoms. It is a serious disease, especially in children under five years of age, who are malnourished and immunocompromised. The transmission of measles is direct, person to person, through nasopharyngeal secretions, expelled when coughing, sneezing, talking or breathing. In 1992, Brazil developed the National Measles Elimination Plan as a strategy to eliminate the disease. In 2000, the last autochthonous outbreaks were confirmed in the states of Acre (AC) and Mato Grosso do Sul (MS). Due to low vaccination coverage, as of 2016, Brazil began to face measles outbreaks in several states, with a high number of cases of the disease. In 2018, the occurrence of the outbreak installed predominantly in the States of Amazonas and Roraima, registering 10,351 measles cases, 12 deaths and the prevalence in a period of more than 12 months, led Brazil to lose certification measles elimination february 2019

Sarampión / Measles

En abril de 2019, UNICEF denunció que más de 20 millones de niños en todo el mundo no habían sido vacunados y alertó sobre posibles brotes de sarampión que, por su alta contagiosidad, es la primera enfermedad en emerger entre las prevenibles mediante vacunación. De continuar el descenso en las vacunaciones, podrían reaparecer también pertussis, tétanos y otras enfermedades con menor requerimiento de cobertura para alcanzar protección poblacional. A fin de agosto de 2019 se inició en la Argentina el actual brote de sarampión. Este virus se transmite por vía respiratoria, infecta múltiples órganos e induce inmunosupresión. Su genoma consiste en ARN de cadena simple. La genotipificación se efectúa por secuenciación de un fragmento de 450 nucleótidos de la proteína N que contiene la mayor densidad de variación de nucleótidos del genoma. En Sudamérica circula el genotipo D8, y en Norteamérica hay, además, un 8% de genotipo B3. Cada persona con sarampión infecta, en promedio, otras 12-18 en una población susceptible. La vacunación confiere protección directa e indirecta, e induce tanto anticuerpos como inmunidad celular. Los recién nacidos tienen protección hasta los 6 meses por anticuerpos maternos transmitidos vía placentaria. En la Argentina, el Calendario de Vacunación incluye dos dosis de triple viral, a los 12 meses y a los 5 años, y una dosis cero (6- 11 meses de edad) en distritos con casos de enfermedad. Una dosis protege al 93% de los vacunados a los 12 meses y dos dosis al 97%, de por vida.

In April 2019, UNICEF denounced that more than 20 million children worldwide had not been vaccinated and alerted on possible outbreaks of measles which, due to the high transmissibility of this virus, is the first disease preventable by vaccination to emerge. If the decline in vaccinations continues, pertussis, tetanus and other diseases, which require less coverage to achieve population protection, may also reappear. In Argentina, the current outbreak began in late August 2019. Measles virus is transmitted by air, infects multiple organs, and is associated with immunosuppression. Its genome consists of single stranded RNA. Genotyping is carried out by sequencing a 450-nucleotide fragment of the N protein, which contains the highest density of nucleotide variation. In South America, D8 is the circulating genotype and in North America, B3 accounts for 8% of the cases. Each person with measles infects, on average, another 12-18 people in a susceptible population. Vaccination confers direct and indirect protection, and induces both antibodies and cellular immunity. Newborns are protected by maternal antibodies transmitted via the placenta, up to 6 months. In Argentina, the Vaccination Calendar includes two doses of triple viral vaccine, at 12 months and 5 years, and a zero dose (6- 11 months of age) in districts with disease cases. The protection conferred by the vaccine is 93% at 12 months with a dose, and with 2 doses 97% for life.

Measles epidemiological profile in Brasil from 2013 to 2018

SUMMARY BACKGROUND To determine the epidemiological profile of measles in Brasil from 2013 to 2018, and to evaluate the possible association between increased number of cases and vaccination coverage. METHODS This is an observational, descriptive, cross-sectional, retrospective study with quantitative approach, carried out through analysis of secondary data collected through the Notifiable Diseases Information System (SINAN), in the National Immunization Program (PNI). RESULTS The total number of reported cases was 10,886, with the year 2018 having the highest number (10,185). In the North macro-region (93.4%), male (55.53%), autochthonous cases from the city of residence (94.42%) and laboratory confirmation (99.09%) predominated. Regarding the age group, it was observed that in the period from 2013 to 2015 the highest prevalence occurred in <1 year, with 44.5%, 40.6% and 29.0%, respectively, while in 2018, the highest rate was in the 20-29 age group with 24.2%. Vaccination coverage was below 95%, except for SCR - D1 (first dose of triple viral) in the years 2013 to 2016. Regarding the outcome, there was a limited number of deaths secondary to measles (0.12%). CONCLUSIONS There was an exponential growth in the number of measles cases in Brasil in 2018, which represents a public health problem. In view of this, it is necessary to implement measures such as broad vaccination coverage and sanitary control at the borders, in order to reduce the incidence of this disease and, consequently, the number of deaths.

RESUMO OBJETIVO Determinar o perfil epidemiológico do sarampo no Brasil no período de 2013 a 2018, além da possível correlação entre incidência de casos e cobertura vacinal. MÉTODO Trata-se uma pesquisa observacional, com delineamento descritivo, transversal, retrospectivo e com abordagem quantitativa, feita por meio de análises de dados secundários coletados no Sistema Nacional de Agravos de Notificação (Sinan), no Programa Nacional de Imunizações (PNI). RESULTADOS O total de casos confirmados foi 10.886, sendo o ano de 2018 com o maior número (10.185). Predominou a macrorregião Norte (93,4%), sexo masculino (55,53%), casos autóctones do município de residência (94,42%) e confirmação laboratorial (99,09%). Com relação à faixa etária, observou-se que, no período de 2013 a 2015, a maior prevalência ocorreu em <1 ano, com 44,5%, 40,6% e 29,0%, respectivamente, enquanto que, em 2018, o maior índice foi na faixa de 20-29 anos, com 24,2%. A cobertura vacinal ficou abaixo de 95%, exceto a SCR - D1 (primeira dose da tríplice viral) nos anos de 2013 a 2016. Quanto ao desfecho, houve limitado número de óbitos secundários ao sarampo (0,12%). CONCLUSÃO Verifica-se um crescimento exponencial no número de casos de sarampo no Brasil em 2018, o que representa um problema de saúde pública. Diante disso, carece que medidas como ampla cobertura vacinal e controle sanitário, nas fronteiras, sejam implementadas, a fim de reduzir a incidência dessa enfermidade e, consequentemente, o número de óbitos.

Falhas vacinais: avaliando vacinas febre amarela, sarampo, varicela e caxumba / Fallos en vacunas: evaluando vacunas de fiebre amarilla, sarampión, varicela y parotiditis / Vaccine failures: assessing yellow fever, measles, varicella, and mumps vaccines

Resumo: A vacinação é uma das maiores intervenções em saúde pública pela segurança e efetividade, porém nem sempre vacinar significa imunizar. Inúmeros aspectos relacionados tanto ao indivíduo que recebe a vacina, quanto à especificidade de cada imunobiológico administrado compõem o processo para a obtenção de uma adequada imunização, sendo essencial que sejam observados para não culminar em falhas vacinais. A análise dos estudos de imunogenicidade e efetividade para as vacinas sarampo, varicela e caxumba apontam para a necessidade da incorporação de duas doses aos calendários básicos de vacinação para o controle das referidas doenças. Estudos epidemiológicos que analisaram surtos dessas doenças identificaram casos em indivíduos que receberam duas doses da vacina, o que pode apontar provável falha secundária. Para a vacina febre amarela, a discussão atual reside no número de doses ideal para a proteção individual. A Organização Mundial da Saúde recomenda dose única para toda a vida. Apesar dos poucos relatos em literatura a respeito das falhas vacinais, os estudos de imunogenicidade demonstram perda de proteção ao longo dos anos, principalmente na faixa etária pediátrica. Num cenário atual de eliminação e controle de doenças, associado à diminuição da circulação de vírus selvagens, o papel da vigilância epidemiológica é fundamental para aprofundar o conhecimento a respeito dos múltiplos fatores envolvidos, que culminam com falhas vacinais e surgimento de surtos. A ocorrência de surtos de doenças imunopreveníveis impacta negativamente a credibilidade dos programas de imunização, acarretando baixas coberturas vacinais e interferindo no êxito da vacinação.

Resumen: La vacunación es una de las mayores intervenciones en salud pública, por su seguridad y efectividad, sin embargo, no siempre vacunar significa inmunizar. Innumerables aspectos relacionados tanto con el individuo que recibe la vacuna, como con la especificidad de cada inmunobiológico administrado, componen el proceso para conseguir una adecuada inmunización, siendo esencial que sean observados para no acabar con fallos en las vacunas. El análisis de los estudios de inmunogenicidad y efectividad para las vacunas sarampión, varicela y parotiditis, apuntan hacia la necesidad de la incorporación de dos dosis a los calendarios básicos de vacunación para el control de las mencionadas enfermedades. Estudios epidemiológicos que analizaron brotes de esas enfermedades identificaron casos en individuos que recibieron dos dosis de la vacuna, lo que puede apuntar un probable fallo secundario. Para la vacuna de fiebre amarilla la discusión actual reside en el número de dosis ideal para protección individual. La Organización Mundial de la Salud recomienda una dosis única para toda la vida. A pesar de los pocos relatos en la literatura, respecto a los fallos en las vacunas, los estudios de inmunogenicidad demuestran una pérdida de protección a lo largo de los años, principalmente en la franja de etaria pediátrica. En un escenario actual de eliminación y control de enfermedades, asociado a la disminución de la circulación de virus salvajes, el papel de la vigilancia epidemiológica es fundamental para profundizar el conocimiento respecto a los múltiples factores implicados, que culminan con fallos en las vacunas y surgimiento de brotes. La ocurrencia de brotes de enfermedades inmunoprevenibles impacta negativamente en la credibilidad de los programas de inmunización, acarreando bajas coberturas de vacunación e interfiriendo en el éxito de la vacunación.

Abstract: Vaccination is one of the greatest public health interventions, based on its safety and effectiveness, but vaccination does not always mean immunization. Numerous aspects related both to the individual that receives the vaccine and the specificity of each vaccine administered are part of the process of obtaining adequate immunization, and it is essential to observe the aspects in order to avoid vaccine failures. The analysis of immunogenicity and effectiveness studies for the measles, varicella, and mumps vaccines point to the need to incorporate two doses into the basic vaccination calendars in order to control these diseases. Epidemiological studies that analyzed outbreaks of these diseases identified cases in individuals that received two doses of the vaccine, which may indicate likely secondary failure. For the yellow fever vaccine, the current discussion lies in the ideal number of doses for individual protection. The World Health Organization recommends a single dose for life. Despite the few reports in the literature concerning vaccine failures, immunogenicity studies demonstrate waning protection over the years, mainly in the pediatric age bracket. In the current scenario of elimination and control of diseases, associated with the decrease in the circulation of the wild-type viruses, the role of epidemiological surveillance is crucial for expanding knowledge on the multiple factors involved, culminating in vaccine failures and the emergence of outbreaks. Outbreaks of vaccine-preventable diseases negatively impact the credibility of immunization programs, leading to low vaccination coverage rates and interfering in vaccination's success.

Sarampión: antecedentes históricos y situación actual / Measles: historical background and current situation

Resumen: El sarampión sigue siendo una causa importante de morbilidad y mortalidad en el niño. Durante estos últimos años, se ha convertido en un problema de salud pública mundial, que se atribuye a bajas coberturas de vacunación observadas en diferentes países. Para su control se dispone de una vacuna a virus vivo, altamente eficaz, que fue empleada por primera vez en Chile en 1964, logrando cobertura en prácticamente todo el país en un breve plazo. Esta fue la primera experiencia mundial, imitada lue go por otros países que resulto en una importante caída de las tasas de morbilidad y de mortalidad. Su eficacia ha sido ampliamente demostrada, pero requiere de la mantención de coberturas superiores a 95%. En Chile persistió una situación de endemia de menor magnitud hasta el año 1993. En años recientes, ha habido algunos brotes reducidos y casos esporádicos vinculados a contactos con casos importados, sin embargo, según datos recientes, el sarampión está circulando ahora en más de 160 países en un nivel de propagación sin precedentes, siendo los viajeros infectados el principal vehículo de transmisión. En Chile, el Ministerio de Salud ha decidido reforzar y poner al día la vacunación de grupos susceptibles, en especial viajeros. En esta actualización se revisan aspectos históricos y la información actual de esta enfermedad que ha resurgido mostrando su alto impacto epidemiológico en la población pediátrica y adulta a nivel global.

Abstract: Measles is still a major cause of child morbidity and mortality. In recent years, it has become a global public health problem, attributed to low vaccination coverage observed in different countries. In order to control it, a highly effective live virus vaccine is available, which was used for the first time in Chile in 1964, covering practically the whole country in a short period of time. This was the first world experience, which was later imitated by other countries leading to a significant drop in mor bidity and mortality rates. Its effectiveness has been amply demonstrated, but it requires coverage maintenance higher than 95%. In Chile, minor endemic situation persisted until 1993. In recent years, there have been some reduced outbreaks and sporadic cases linked to contacts with imported cases, however, according to recent data, measles is now circulating in more than 160 countries at an unprecedented spread level, where infected travelers are the main vehicle of transmission. In Chile, the Ministry of Health has decided to strengthen and update the vaccination of susceptible groups, especially travelers. This update reviews historical aspects and current information on this re-emer ging disease, showing its high epidemiological impact on the pediatric and adult population globally.

Riesgo de contagio de sarampion para un viajero chileno en 2017 / Calculating the risk of acquiring measles of chileans traveling abroad

Background: There is always a risk of importing infectious diseases when travelling abroad. Aim: To estimate the effective risk of a Chilean of acquiring measles during a travel by countries where measles outbreaks have been reported, considering the present level of immunity in the country. Material and Methods: Previously established mathematical models using differential equations were applied to calculate the risk of acquiring measles of people traveling to endemic areas. Results: The probability of acquiring measles of a voyager is 8.11 x 10-8. Conclusions: These estimations help decision making about preventive measures for travelers to endemic measles areas.

Editorial: Sarampión: Una epidemia prevenible / Editorial Measles: A preventable epidemic

El sarampión una enfermedad que en el siglo IX (860-932)fue descrita por el médico persa Muhammad ibn Zacariya al-Razi quien la diferenció de la viruela por sus síntomas y signos clínicos .